Fortis Healthcare FY25 Results: Revenue Rises 12.9% to ₹7,783 Crore

Fortis Healthcare Limited announced its financial results for the fourth quarter and full year ended March 31, 2025, reporting growth across its hospital and diagnostic businesses.

Q4 Financial Highlights

For Q4 FY25, consolidated revenues rose by 12.4% year-on-year to ₹2,007 crore, while operating EBITDA increased by 14.3% to ₹435 crore, with margins improving to 21.7% from 21.3% in Q4 FY24.

Hospital business revenues grew by 14.2% to ₹1,701 crore, while the segment’s operating EBITDA rose 11.7% to ₹372 crore. However, margins slightly declined to 21.9% from 22.4% in the same quarter last year.

The diagnostics business recorded revenue of ₹306 crore, with margins increasing to 20.4% from 16% in Q4 FY24. Excluding one-off rebranding expenses, diagnostic EBITDA margins stood at 26.7%, compared to 18.6% in the previous year.

FY25 Performance Driven by Hospital Segment

For the full financial year FY25, Fortis reported a 12.9% increase in consolidated revenue at ₹7,783 crore. Operating EBITDA grew by 25.3% to ₹1,588 crore, with margins improving significantly to 20.4% from 18.4% in FY24. The hospital business contributed to the performance, with revenues up 14.8% to ₹6,528 crore and EBITDA up 26.6% to ₹1,339 crore, leading to margins of 20.5%.

The diagnostic business also saw a steady increase, with FY25 revenue rising to ₹1,255 crore from ₹1,207 crore in FY24. Operating margins improved to 19.8% from 17.3%. After adjusting for rebranding-related one-offs, full-year EBITDA margins for diagnostics stood at 24.6%, compared to 22.3% last year.

Strategic Brand Acquisition and Dividend Declaration

In a significant strategic move, the company acquired the perpetual rights to the ‘Fortis’ brand for ₹200 crore. The Board also recommended a dividend of ₹1 per share (10% of face value) for FY25.

Balance Sheet Update

Fortis closed FY25 with a net debt of ₹1,694 crore, with a net debt-to-EBITDA ratio of 0.93x, up from 0.17x in FY24. The increase was primarily due to funding the acquisition of a 31.5% stake in Agilus Diagnostics. Net debt-to-equity stood at 0.18x.

Fortis Healthcare Share Price Performance

On May 20, 2025, Fortis share price opened at ₹693.70 and closed at ₹681.95, down by 0.57%. The stock price touched its day’s low at ₹675.00.

Also Read: Fortis Healthcare Secures Fortis Trademark Ownership For ₹200 Crore!

Conclusion

Fortis Healthcare’s operational performance, strategic brand consolidation, and expanding margins underscore its continued growth trajectory, despite a rise in leverage due to investment activity.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.